Lumateperone Improves Depressive Symptoms Among Patients With Bipolar Disorder
Investigators assessed the safety and efficacy of lumateperone for the treatment of bipolar I and II disorders in patients experiencing major depressive episodes.
Investigators assessed the safety and efficacy of lumateperone for the treatment of bipolar I and II disorders in patients experiencing major depressive episodes.
Clinical trials have not yet put a focus on early intervention for psychosocial impairment nor have clinical trials examined the contribution of components of borderline personality disorder treatment except for individual psychotherapy. Researchers in this study looked at which combination of treatment components is adequate for an early intervention for young people with borderline personality disorder.
In between manic and depressive episodes, symptoms including disturbed sleep and impulsivity remain. Both these symptoms can predict the onset of bipolar disorder. The researchers investigated these core bipolar disorder features as potential risk factors for bipolar disorder.
People with severe mental illness (SMI) have higher risks for COVID-19 infection, hospitalization, and mortality.
Researchers are exploring affective lability as a therapeutic target for bipolar disorder, but limited evidence exists on its prevalence and impact among people with schizophrenia and other psychosis spectrum disorders.
In a recent survey, more than half the college students with ADHD had at least 1 psychiatric disorder. The recent WHO World Mental Health Survey of college students assessed comorbidities in more than 15,000 college freshmen across 9 countries.
Researchers examined hospitalization rates among pediatric patients with bipolar disorder who received treatment with atypical antipsychotic drugs.
Investigators evaluated the impact of acute psychosocial stress on changes in amygdala activation and functional connectivity among young adults with bipolar disorder.
Investigators conducted a systematic review and meta-analysis to assess the effect of pharmacotherapy on anxiety symptoms in individuals with bipolar disorder.
Investigators assessed the relationship between clinical and cognitive features and oddball neural deviations across the schizophrenia-bipolar spectrum.